Heterocyclic derivatives as modulators of ion channels
申请人:Martinborough Esther
公开号:US20080027067A1
公开(公告)日:2008-01-31
The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
Selective C–H Olefination of Indolines (C5) and Tetrahydroquinolines (C6) by Pd/S,O-Ligand Catalysis
作者:Wen-Liang Jia、Nick Westerveld、Kit Ming Wong、Thomas Morsch、Matthijs Hakkennes、Kananat Naksomboon、M. Ángeles Fernández-Ibáñez
DOI:10.1021/acs.orglett.9b03505
日期:2019.12.6
highly selective C-Holefination of directing-group-free indolines (C5) and tetrahydroquinolines (C6) by Pd/S,O-ligand catalysis. In the presence of the S,O-ligand, a wide range of challenging indolines, tetrahydroquinolines, and olefins was efficiently olefinated under mild reaction conditions. The synthetic potential of this methodology was demonstrated by the efficient olefination of several indoline-based
Iron-Mediated Selective Sulfonylmethylation of Aniline Derivatives with <i>p</i>-Toluenesulfonylmethyl Isocyanide (TosMIC)
作者:Yigao Li、Xu-Yan Wang、Xiaohuang Ren、Baoheng Dou、Xinju Zhu、Xin-Qi Hao、Mao-Ping Song
DOI:10.1021/acs.joc.1c00500
日期:2021.5.21
An iron-mediated highly selective C–H sulfonylmethylation of anilinederivatives with p-toluenesulfonylmethyl isocyanide in a mixture solvent of H2O and PEG400 under an Ar atmosphere has been realized. This transformation proceeds with operational convenience, use of earth-abundant metal catalyst and nontoxic media, broad substrate scope, and good functional group tolerance. The current methodology
[EN] COMPOUNDS AS RAS INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DE RAS ET LEURS UTILISATIONS
申请人:BIOARDIS LLC
公开号:WO2022087624A1
公开(公告)日:2022-04-28
The present disclosure relates generally to compounds and compositions thereof for inhibition of RAS, such as KRAS, HRAS and NRAS, including mutant forms of KRAS, HRAS and NRAS, particularly those harboring a G12C mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung cancer, colorectal cancer, pancreatic cancer, gall bladder cancer, thyroid cancer, and bile duct cancer.
PYRIDYL SULFONAMIDES AS MODULATORS OF ION CHANNELS
申请人:Martinborough Esther
公开号:US20090105271A1
公开(公告)日:2009-04-23
The present invention relates to pyridyl sulfonamide derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.